Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionSignaturefd, Llc
Latest Disclosed Ownership2,047 shares
Latest Disclosed Value $ 677,443
Signaturefd, Llc reports 3.33% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 7, 2026 - Signaturefd, Llc filed a 13F-HR form disclosing ownership of 2,047 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $584,828 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 1,981 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 3.33% during the quarter. The current value of the position is $533,244 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-07 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,047 66 3.33 677 -13.98 0.0104
2026-01-20 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,981 -17 -0.85 788 -13.61 0.0120
2025-10-21 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,998 92 4.83 911 46.70 0.0144
2025-07-16 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,906 151 8.60 622 31.29 0.0106
2025-05-02 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,755 115 7.01 474 22.86 0.0090
2025-02-10 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,640 -214 -11.54 386 -24.51 0.0073
2024-10-21 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,854 471 34.06 510 51.79 0.0097
2024-07-29 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,383 284 25.84 336 104.88 0.0068
2024-05-03 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,099 -90 -7.57 164 -27.75 0.0035
2024-02-01 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,189 14 1.19 228 9.13 0.0053
2023-11-03 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,175 -493 -29.56 208 -34.18 0.0054
2023-08-01 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,668 223 15.43 317 9.34 0.0081
2023-04-28 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,445 -159 -9.91 289 -24.15 0.0079
2023-01-30 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,604 59 3.82 381 23.30 0.0111
2022-11-08 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,545 1,057 216.60 309 335.21 0.0106
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 488 -510 -51.10 71 -56.44 0.0024
2022-05-02 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 998 75 8.13 163 3.82 0.0049
2022-01-25 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 923 -29 -3.05 157 -12.78 0.0048
2021-10-28 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 952 12 1.28 180 13.21 0.0062
2021-07-26 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 940 136 16.92 159 39.47 0.0063
2021-04-30 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 804 -149 -15.63 114 -8.06 0.0050
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 953 473 98.54 124 77.14 0.0058
2020-11-03 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 480 245 104.26 70 100.00 0.0037
2020-07-30 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 235 45 23.68 35 66.67 0.0021
2020-04-23 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190 141 287.76 21 250.00 0.0018
2020-02-05 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49 17 53.12 6 100.00 0.0004
2019-10-16 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32 0 0.00 3 50.00 0.0002
2019-07-31 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32 32 2 0.0002
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -61 -100.00 0 -100.00
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61 0 0.00 5 -16.67 0.0005
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61 35 134.62 6 100.00 0.0007
2018-05-08 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26 26 3 0.0004
2016-07-29 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -37 -100.00 0 -100.00
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37 37 0.00 2 0.0003
2016-01-22 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -20 -100.00 0 -100.00
2015-10-23 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20 20 2 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.